Thrombosis Journal最新文献

{"title":"Associations between rivaroxaban dose, gut microbiota, and coagulation parameters in a rat model.","authors":"Yuanyuan Liu, Yi Zhang, Yang Yang, Chang Han, Yong Zhang, Jingtao Zhou","doi":"10.1186/s12959-025-00817-6","DOIUrl":"10.1186/s12959-025-00817-6","url":null,"abstract":"<p><p>Rivaroxaban, a direct oral anticoagulant, is widely prescribed for thrombotic disorders, yet growing evidence suggests that gut microbiota may influence its pharmacodynamic effects. This study investigated dose-dependent associations between rivaroxaban administration, gut microbiota composition, and coagulation parameters in a rat model. Twenty-four rats were assigned to control, low-, medium-, and high-dose rivaroxaban groups. After 30 days of administration, 16S rRNA sequencing and plasma coagulation analyses were performed. Rivaroxaban treatment was associated with significant, dose-related alterations in gut microbiota diversity and composition, notably decreasing Allobaculum and increasing Ligilactobacillus faecis abundance. Additionally, Lactobacillus johnsonii exhibited an initial increase followed by a decline at higher doses. Coagulation parameters—prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) were prolonged, and fibrinogen (FIB) levels decreased in a dose-dependent manner. Correlation analyses revealed associations between microbial shifts and coagulation indices. These findings indicate associations rather than causation and highlight the need for further mechanistic studies, including models with altered baseline microbiota, to determine whether specific microbial changes modulate rivaroxaban response.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"11"},"PeriodicalIF":2.7,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiphospholipid syndrome presents with aortic thrombosis and central venous catheter-related thrombosis: a case report.","authors":"Yujiao Chen, Dongjing Li, Yinghong Su, Yulong Zhang","doi":"10.1186/s12959-025-00815-8","DOIUrl":"10.1186/s12959-025-00815-8","url":null,"abstract":"<p><strong>Background: </strong>Antiphospholipid syndrome (APS) is a prothrombotic autoimmune disorder in which perioperative factors-particularly cardiopulmonary bypass-may amplify hypercoagulability. Evidence and consensus guidance for APS management around cardiovascular surgery remain limited. A 37-year-old man with a large, highly mobile thrombus in the ascending aorta underwent surgical thrombectomy under cardiopulmonary bypass. Preoperative testing showed only leukocytosis, slightly shortened activated partial thromboplastin time (APTT) and mild D-dimer elevation; all other findings were unremarkable. Ten days postoperatively, removal of a nontunneled right internal jugular central venous catheter (CVC) was unexpectedly impeded by catheter-related thrombosis (CRT) despite prophylactic anticoagulation. Noninvasive maneuvers failed to free the catheter, necessitating open surgical extraction. Subsequent evaluation revealed widespread venous thromboses and confirmed APS, likely underlying both the arterial event and the rapidly developing catheter-associated thrombosis. Aggressive multimodal therapy-including methylprednisolone, enteric-coated aspirin, warfarin, rituximab, unfractionated heparin, and fibrinogenase-achieved clinical stabilization and prevented further events.</p><p><strong>Conclusion: </strong>This case highlights the challenges in timely diagnosing APS and the management complexity of rapid, postoperative thrombus formation. Clinicians should maintain a high index of suspicion for early postoperative hypercoagulability-even when routine coagulation screens are unrevealing-escalate promptly when CVC removal meets resistance, and consider APS-tailored antithrombotic strategies. The possibility that fibrin sheaths and catheter-associated thrombosis can evolve quickly, even after short indwelling times, warrants vigilance and early multidisciplinary intervention. It also raises concern that, in this context, standard direct oral anticoagulants (DOACs) may be less effective.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"10"},"PeriodicalIF":2.2,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic and clinical characterization of two families with severe venous thromboembolism due to nonsense mutations in the SERPINC1 gene.","authors":"Xuqian Wei, Weibin Chen, Jian Zhang, Jianhua Mao","doi":"10.1186/s12959-025-00803-y","DOIUrl":"10.1186/s12959-025-00803-y","url":null,"abstract":"<p><p>Antithrombin (AT) III is a key physiological anticoagulant, and its hereditary deficiency represents one of the most severe forms of inherited thrombophilia. However, as a rare disorder, AT III deficiency is frequently underdiagnosed due to the limitations of current clinical algorithms. In this study, we describe two cases of hereditary AT III deficiency accompanied by multiple venous thromboembolic events: a 39-year-old male with extensive lower limb deep venous thrombosis (DVT) involving the iliac, femoral, and popliteal veins, and a 21-year-old female with intermediate-high risk pulmonary embolism (PE). Laboratory evaluation revealed reduced AT III activity levels of 51.9% and 52.7%, respectively. Quantitative ELISA analysis further confirmed a corresponding reduction in AT antigen levels. Both patients showed suboptimal responses to initial low-molecular-weight heparin treatment but responded favorably to oral rivaroxaban. Genetic testing identified two nonsense mutations in the SERPINC1 gene: NM_000488.4:c.906dupT (p.Glu303Ter), a previously unreported variant, and NM_000488.4:c.481 C > T (p.Arg161Ter), reported here for the first time in an Asian individual. Family analyses confirmed that the variants were inherited from the proband's parents, who had a history of venous thromboembolism (VTE). These findings underscore the importance of assessing AT activity in patients with unexplained thrombotic events, particularly at a young age, and support the use of genetic testing to guide personalized anticoagulation strategies in AT III deficiency.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"118"},"PeriodicalIF":2.2,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12690778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145715860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of anticoagulation dose reduction for venous thromboembolism prophylaxis in low body weight patients: a systematic review and meta-analysis.","authors":"Ian Gabriel Alparaque Juyad, Rochelle Ivy A Cion, Genquen Philip Carado, Jerahmeel Aleson L Mapili, Deonne Thaddeus V Gauiran, Elaine B Alajar","doi":"10.1186/s12959-025-00806-9","DOIUrl":"10.1186/s12959-025-00806-9","url":null,"abstract":"<p><p>BACKGROUND: Venous thromboembolism (VTE) is a common complication among hospitalized patients, hence VTE prophylaxis is essential. Low body weight patients are at an increased risk of bleeding however there are no guideline recommendations regarding dose adjustment in this population. We performed a meta-analysis to determine whether dose reduction for VTE prophylaxis in low-body weight patients reduces the risk of bleeding, without compromising its efficacy. METHODS: We searched electronic databases from inception to October 2024. We did a random-effects meta-analysis using RevMan 5.4. Data were pooled to obtain a risk ratio (RR) with 95% confidence interval (CI). Heterogeneity and publication bias were assessed with statistic and funnel plot, respectively. Risk of bias was assessed using ROBINS-I and certainty of evidence was assessed using GRADE. RESULTS: Seven observational studies with 5,575 individuals were included. Pooled analyses revealed no significant difference in risk of total bleeding [RR 0.78, 95% CI 0.48–1.26] and major bleeding [RR 0.62, 95% CI 0.33–1.15] with reduced dose compared to standard dose anticoagulation, however with high heterogeneity (I2 = 64%). Excluding studies with baseline characteristics increasing risk of bleeding in the reduced dose group, sensitivity analysis showed that dose reduction significantly decreases the risk of total [RR 0.49, 95% CI 0.30–0.82] and major bleeding [RR 0.42, 95% CI 0.22–0.80], with low heterogeneity (I = 0). In terms of efficacy, there is not enough evidence to show that anticoagulation dose reduction increases risk of VTE [RR 0.74, 95% CI 0.32–1.73]. CONCLUSION: Among low body weight patients, dose reduction for VTE prophylaxis may reduce risk of bleeding, especially major bleeding, without compromising its efficacy in preventing VTE, hence it can be considered in this population. Randomized controlled trials are needed to further support this recommendation. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"7"},"PeriodicalIF":2.7,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12801602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145715835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The correlation of lupus anticoagulant and anticardiolipin antibodies with hematological parameters and clinical findings in sickle cell disease at steady state phase.","authors":"Mohammed Aw Almorish, Ahmed M E Elkhalifa, Moataz Mohamedalhasan Ali, Isameldin Mohamed Abdalla Hamad, Omer M Aburaida, Rabei M Elbadry, Yasir S Kaloda, Elfatih Mirghani M Salih, Khaled Mohammed Al-Sayaghi, Mohammed A Hameed Albalawi, Maher M Aljohani, Burhanudin Saha","doi":"10.1186/s12959-025-00813-w","DOIUrl":"10.1186/s12959-025-00813-w","url":null,"abstract":"<p><strong>Background: </strong>Current therapeutic interventions for Sickle Cell Disease (SCD) have improved patient survival; however, the clinical determinants of elevated autoantibody prevalence and related complications in patients with SCD remain insufficiently elucidated.</p><p><strong>Objective: </strong>This study aimed to examine the frequency of lupus anticoagulant (LA), anticardiolipin antibody (aCL), and anti-beta2 glycoprotein I antibodies (anti- β2GPI) in patients with SCD at steady state phase to evaluate their possible correlations with hematological factors and clinical complications.</p><p><strong>Methods: </strong>This cross-sectional study involving 92 SCD patients in a steady state phase was conducted. Blood specimens were obtained for complete blood count (CBC), in conjunction with the identification of IgG for aCL and anti-β2GPI utilizing enzyme-linked immunosorbent assay (ELISA) and the assessment of LA through the Diluted Russell Viper Venom Time (dRVVT).</p><p><strong>Results: </strong>The prevalence of LA, aCL, and anti-β2GPI (IgG) in SCD patients at steady state was 29.4%, 16.3%, and 5.4%, respectively. A correlation was found between LA and chronic leg ulcers, history of thrombosis, decreased platelet counts (PLT), and increased mean platelet volume (MPV) in SCD patients. Furthermore, aCL (IgG) exhibited a significant association with chronic leg ulcers, history of thrombosis, elevated Hemoglobin (Hb) levels, increased red blood cell count (RBC), and higher red cell distribution width (RDW) in SCD patients at steady state phase.</p><p><strong>Conclusion: </strong>This research elucidates the incidence of LA and aCL in SCD patients during steady state, linking these autoantibodies to hematological parameters and clinical complications; thus, prospective assessments of aPL in SCD patients are essential.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"23 1","pages":"117"},"PeriodicalIF":2.7,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12687473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145709826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term patency of the transjugular intrahepatic portosystemic shunt for portal and superior mesenteric vein thrombosis.","authors":"Junyang Luo, Churen Zhou, Yanyang Zhang, Haofan Wang, Caiyun Lu, Jialin Wu, Jie Qin, Zaibo Jiang, Junwei Chen","doi":"10.1186/s12959-025-00799-5","DOIUrl":"10.1186/s12959-025-00799-5","url":null,"abstract":"<p><p>BACKGROUND: This retrospective study evaluated the long-term patency of transjugular intrahepatic portosystemic shunt (TIPS) placement and identified predictors of shunt dysfunction in patients with portal and superior mesenteric vein thrombosis (PSVT). METHODS: From January 2018 to January 2024, patients with symptomatic PSVT who underwent TIPS were enrolled. Clinical variables, imaging features, adverse events, and clinical outcomes were recorded. The cumulative rate of TIPS patency rates were calculated using the Kaplan-Meier method, with subgroup comparisons performed by the log-rank test. Independent predictors of shunt dysfunction were identified via Cox regression analysis. RESULTS: Forty-nine patients (mean age 47.8 ± 12.5 years; 79.6% male) were successfully treated with TIPS. Among them, 69.4% had cirrhosis and 49.0% had hepatitis B virus infection, with cirrhosis-related portal hypertension being the most common etiology of thrombosis. The 6-, 12-, and 24-month primary patency rates were 70.8% (95% CI: 59.0–85.0%), 66.4% (95% CI: 54.3–81.3%), and 56.5% (95% CI: 43.7–73.1%), respectively. Multivariate analysis identified sufficient inflow (patency of the splenic vein or an inflow vein diameter > 8 mm) and the use of covered stents in the main portal vein as independent predictors of TIPS patency. CONCLUSIONS: TIPS can be safely performed in patients with PSVT. Adequate inflow and the use of covered stents in the main portal vein are important factors for long-term TIPS patency. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"6"},"PeriodicalIF":2.7,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12797656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective study on the clinical outcomes of endovascular intervention treatment for inferior vena cava filter thrombosis.","authors":"Shiqiang Liao, Shuming Shi, Chuanyong Li, Guangfeng Zheng, Qiang Zhang, Zhichang Pan, Jianjie Rong","doi":"10.1186/s12959-025-00805-w","DOIUrl":"10.1186/s12959-025-00805-w","url":null,"abstract":"<p><p>INTRODUCTION: To explore the feasibility and safety of various endovascular intervention methods for the treatment of inferior vena cava filter thrombosis. METHODS: A retrospective analysis was performed on 31 patients who were treated in our center from January 2020 to December 2022 with diagnosis of inferior vena cava filter thrombosis (IVCFT). Manual aspiration thrombectomy (MAT), catheter-directed thrombolysis (CDT), AngioJet rheolytic thrombectomy (ART), and balloon dilatation and stent implantation, either individually or in combination of 2 or 3 methods, were applied. Data of the thrombus clearance rate, inferior vena cava filter (IVCF) retrieval rate, thrombus status in the IVCF after retrieval of the filters, patency of inferior vena cava (IVC), and complications were collected and analyzed. RESULTS: MAT was applied in 6 cases, CDT was applied in 10 cases, CDT plus MAT was used in 7 cases, ART plus CDT was used in 5 cases, combination of ART, CDT and MAT was used in 2 cases, and balloon dilatation and stent implantation following CDT was used in 1 case. The success rate of surgical technique in 31 patients was 100%. Except one primary filter, which was placed in other hospital 5 years ago, the rest 30 primary filters plus a secondary protective filter placed in one of the patients were successfully removed. Grade II or III was achieved in thrombus clearance by the endovascular mechanical therapies in this study. The restoration rate of IVC patency was 100%. No serious complications such as massive hemorrhage or pulmonary embolism occurred during the procedure of the endovascular intervention therapies. CONCLUSIONS: Endovascular intervention therapies, including MAT, CDT, ART, and stent implantation, are safe and feasible in IVCF retrieval and restoration of IVC venous patency. CLINICAL TRIAL NUMBER: Not applicable. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"3"},"PeriodicalIF":2.7,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of anticoagulant therapy in patients with sepsis: a meta-analysis of randomized controlled trials.","authors":"Qi Wang, JiaYu Wu, WenHao Tang, Hong Zhang","doi":"10.1186/s12959-025-00812-x","DOIUrl":"10.1186/s12959-025-00812-x","url":null,"abstract":"<p><strong>Background: </strong>Coagulation dysfunction significantly impacts sepsis prognosis. Standardized methods for evaluating anticoagulant efficacy and safety in this population remain lacking. This study aimed to assess the efficacy and safety of anticoagulant therapy in sepsis patients.</p><p><strong>Methods: </strong>We systematically searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) comparing anticoagulants against placebo/no treatment in sepsis patients. The reduction in 28/30-day all-cause mortality or the regression of disseminated intravascular coagulation (DIC) was regarded as efficacy endpoints, while bleeding complications constituted the most prevalent adverse events.</p><p><strong>Results: </strong>Eighteen RCTs involving 8053 patients were included. Anticoagulant therapy demonstrated an 8% mortality risk reduction versus placebo (relative risk [RR] 0.92, 95% CI 0.86-0.98; P = 0.02). In six studies of baseline DIC patients, anticoagulants showed non-significant mortality reduction (RR 0.87, 95% CI 0.62-1.22; P = 0.42) but significantly enhanced DIC regression (RR 1.62, 95% CI 1.32-2.00; P < 0.00001). Anticoagulants increased bleeding risk (RR 1.32, 95% CI 1.16-1.49; P < 0.0001).</p><p><strong>Conclusion: </strong>Anticoagulant therapy confers survival benefit in the overall sepsis population despite increased bleeding risk. While improving DIC regression in sepsis-associated DIC, mortality reduction in this subgroup lacked statistical significance. Further research should clarify anticoagulants' role in DIC-specific sepsis management.</p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"4"},"PeriodicalIF":2.2,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145661155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular diagnosis of inherited platelet disorders: a tale of two realities - advanced vs. resource-limited setting.","authors":"Seyed Mehrab Safdari, Sina Jozdani, Mahsa Mottaghizadeh-Jazi, Maryam Shayanmanesh, Alireza Khanahmad, Mehdi Bakhtiyaridovvombaygi, Azadeh Rezazadeh, Shadi Tabibian","doi":"10.1186/s12959-025-00797-7","DOIUrl":"10.1186/s12959-025-00797-7","url":null,"abstract":"<p><p>BACKGROUND: Inherited platelet disorders are a heterogeneous group of rare conditions characterized by impaired platelet production or function, often leading to significant bleeding complications. Accurate diagnosis is essential for effective management and improved patient outcomes. However, the complexity of these disorders, coupled with the reliance on sophisticated diagnostic technologies, presents substantial challenges, particularly in settings with limited resources. MAIN BODY: This narrative review examines the advancements and challenges in the molecular diagnosis of inherited platelet disorders, highlighting the stark contrast between advanced and resource-limited healthcare environments. In high-income regions, cutting-edge molecular techniques, such as next-generation sequencing (NGS), have transformed diagnostic precision by accurately identifying genetic mutations, enabling tailored treatment strategies and better prognostic insights. Nevertheless, genetic testing is not routinely employed as a first-line diagnostic tool, even in advanced centers, because conventional phenotypic and paraclinical methods, including coagulation assays, platelet function studies, flow cytometry, immunofluorescence, and electron microscopy, remain essential for establishing initial diagnoses. These tests often suffice in characterizing severe or classical phenotypes, with molecular analysis serving as a confirmatory or complementary approach when needed. Conversely, in resource-limited settings, access to advanced genetic platforms is restricted due to cost, infrastructure, and expertise barriers, leading to delayed or incomplete diagnoses and continued reliance on less specific clinical or laboratory evaluations. Bridging this divide requires context-appropriate strategies, such as cost-effective genetic testing platforms, strengthened international collaboration, and capacity-building initiatives. CONCLUSION: Bridging the diagnostic gap in inherited platelet disorders demands a global commitment to equitable healthcare delivery. By prioritizing affordable diagnostic solutions and fostering collaborative efforts, it is possible to ensure that all patients, irrespective of geographic or economic circumstances, benefit from timely and precise diagnoses. Such efforts promise to enhance treatment efficacy, reduce morbidity, and elevate the quality of life for individuals affected by these complex disorders. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"119"},"PeriodicalIF":2.7,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12696962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145640039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features and risk factors for poor prognosis in malignant tumor patients with pulmonary embolism: a case control study.","authors":"Kexin Dong, Hongyuan Kong, Lin Wang, Zhonghui Yu, Xinyan Lu, Zhaoxing Cui, Jin Yang, Yuxin Xia, Beibei Zhang, Zhenkun Li","doi":"10.1186/s12959-025-00811-y","DOIUrl":"10.1186/s12959-025-00811-y","url":null,"abstract":"<p><p>BACKGROUND: Pulmonary embolism (PE) is a significant cause of death in cancer patients. Although there are many reports on the clinical features and In-hospital prognosis for PE, but few studies on malignant tumors combined with pulmonary embolism. Early identification of high-risk populations, enhanced monitoring, and targeted therapeutic measures are crucial for improving patient prognosis. We conducted this study to identify reliable prognostic indicators through the analysis of real-world data. METHODS: A total of 471 patients of malignant tumors complicated with PE were divided into two groups: (1) PE with poor prognosis group (n = 146). (2) PE without poor prognosis group (n = 325). Clinical characteristics, laboratory parameters and adverse prognostic events were recorded and analyzed. RESULTS: High diastolic blood pressure (Odds Ratio [OR] = 1.819, 95% confidence interval [CI]: 1.144–2.893, p = 0.011), myoglobin (MYO) (OR = 3.283, 95% CI: 2.016–5.347, p < 0.001), procalcitonin (PCT) (OR = 2.530, 95% CI: 1.581–4.049, p < 0.001), pleural effusion (OR = 1.618, 95% CI: 1.013–2.584, p = 0.044) and invasive surgery (OR = 2.339, 95% CI: 1.471–3.719, p < 0.001) were found to be independent risk factors for poor prognosis in malignant tumor patients with PE. The ROC curve analysis showed that the area under the curve (AUC) for MYO and PCT were 0.683 and 0.657, respectively. The combined predictive value of MYO and PCT was 0.704. CONCLUSION: High diastolic blood pressure, MYO, PCT, pleural effusion, invasive surgery were proved to be independent risk factors for poor prognosis in malignant tumor patients with PE. In biomarkers, the indicator of MYO combined with PCT shows the highest predictive value. </p>","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":" ","pages":"123"},"PeriodicalIF":2.7,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12750809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145606152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}